Bill is not perfect but the decision to not enter into the agreement with phot was. There should be some kind of fund where shareholders get their money back. Read the following.
One of the key aspects of PHOT's future potential related to its agreement with CEN Biotech and RXNB. CEN had been approved to build a medical marijuana growing facility in Canada which could produce 1.3 million pounds of dried marijuana annually. It is noted that CEN is a subsidiary of Creative Edge Nutrition (OTC:OTCPK:FITX). On Apr 11, 2014, both CEN Biotech and RXNB rescinded all agreements and terminated their relationship with PHOT further hampering Growlife's potential at becoming a seasoned marijuana player. PHOT's potential partners (CEN Biotech and RXNB) obviously realized, that the shares they were to receive in consideration for the transaction (over 500 million shares were to be issued in total), would be close to worthless when PHOT's shares resume trading. The loss of this deal is a hard blow for PHOT in the medium-term.
On Apr 21, 2014, if PHOT did not have enough issues on its plate, Tripp Levy PLLC announced a class action lawsuit on behalf of purchasers of PHOT securities between Nov 14, 2013 and Apr 9, 2014.
Conclusion